Top of this page
Skip navigation, go straight to the content

UCB0599

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Early-stage Parkinson's Disease
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Phase 2 PD0053
Ongoing
NCT04658186